Next-gen CAR-T play­er steps on the gas with a $111M boost and a pos­i­tive glimpse at ear­ly da­ta

Though Imm­PACT Bio was tech­ni­cal­ly found­ed in Is­rael back in 2017, in­com­ing CEO Sumant Ra­machan­dra says the com­pa­ny was re­born last year when it merged with UCLA spin­off Kalthera. Now, with $111 mil­lion more to work with, the new chief ex­ec­u­tive is step­ping on the gas.

Imm­PACT Bio un­veiled a mas­sive Se­ries B round ear­ly Thurs­day morn­ing, along with a C-suite shake­up and a first glimpse at some Phase I da­ta. Sev­en of eight pa­tients with re­lapsed or re­frac­to­ry B cell non-Hodgkin’s lym­phoma giv­en the com­pa­ny’s lead can­di­date — a CD19/CD20 bis­pe­cif­ic CAR-T — achieved com­plete re­mis­sion af­ter a me­di­an fol­low-up of 12 months, Ra­machan­dra said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER